Terbinafine-induced cholestatic liver disease

Journal of Hepatology

Volumn 24, Issue 6, 1996, Pages 753-756

  Lazaros, George A ^a   Papatheodoridis, George V ^a   Delladetsima, Johanna K ^b   Tassopoulos, Nicolaos C ^a  

^a Western Attica General Hospital   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Adverse effects; Antifungal; Cholestasis; Liver disease; Terbinafine

Indexed keywords

TERBINAFINE;

ADULT; ARTICLE; CASE REPORT; CHOLESTASIS; FEMALE; HUMAN; LIVER DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030175615     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80273-X     Document Type: Article

References (16)

1. Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs. 43:1992;259-284.
2. Goodfield MJD, Rowell NR, Forster RA, Evans EGV, Raven A. Treatment of dermatophyte infection of the finger and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. Br J Dermatol. 121:1989;753-757.
3. Finlay AY. Global overview of Lamisil. Br J Dermatol. 130:1994;1-3. (Suppl 43).
4. Cole GW, Stricklin G. A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis. Arch Dermatol. 125:1989;1537-1539.
5. Allen BR, Cowley N, Dawber R, Evans EGV, Finlay AY, Forster RA, Goodfield M, Harland C, Lever L, O'Sullivan D, Pepper M, Raven A, Roberts DT, Rowell N, Telfer N, Tidman M, Wilkinson JD. Oral terbinafine: effective in the treatment of chronic nail dermatophytosis. Br J Dermatol. 121:1989;16. (Suppl. 34).
6. Lowe G, Green C, Jennings P. Hepatitis associated with terbinafine treatment. Br Med J. 306:1993;248.
7. Van't Wout JW, Hermann WA, de Vries RA, Stricker BHCh. Terbinafine-associated hepatic injury. J Hepatol. 21:1994;115-117.
8. Villars V, Jones TC. Present status of the efficacy and tolerability of terbinafine (Lamisil) used systematically in the treatment of dermatomycoses of skin and nails. J Dermatol Treat. 1:1990;33-38. (Suppl. 2).
9. Juhlin L. Loss of taste and terbinafine. Lancet. 339:1992;1483.
10. Ottervanger JP, Stricker BHCh. Loss of taste and terbinafine. Lancet. 340:1992;728.
11. Carstens J, Wendelboe P, Sogaard H, Thestrup-Pedersen K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Venereol. 74:1994;391-392.
12. Ishak KG, Irey NS. Hepatic injury associated with the phenothiazines. Arch Pathol. 93:1972;283-304.
13. Horst DA, Grace ND, Lecompte PM. Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy. Gastroenterology. 79:1980;550-554.
14. Larrey D, Amouyal G, Pessayre D, Degott C, Danne O, Machayekhi JP, Feldmann G, Benhamou JP. Amitriptyline-induced prolonged cholestasis. Gastroenterology. 94:1988;200-203.
15. Larrey D, Pessayre D, Duhamel G, Casier A, Degott C, Feldmann G, Erlinger S, Benhamou JP. Prolonged cholestasis after ajmaline-induced acute hepatitis. J Hepatol. 2:1986;81-87.
16. Benichou C. Criteria of drug-induced liver disorders. J Hepatol. 11:1990;272-276.